Literature DB >> 26104823

Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience.

Chan-Young Ock1, Bhumsuk Keam1,2, Yoojoo Lim1, Tae Min Kim1,2, Se-Hoon Lee1,2, Seong Keun Kwon2,3, J Hun Hah2,3, Tack-Kyun Kwon3, Dong-Wan Kim1,2, Hong-Gyun Wu4, Myung-Whun Sung2,3, Dae Seog Heo1,2.   

Abstract

BACKGROUND: Although induction chemotherapy can reduce distant metastases in locally advanced head and neck squamous cell carcinoma (HNSCC), overall survival (OS) improvement because of induction chemotherapy has not been confirmed.
METHODS: We reviewed medical records of 224 patients diagnosed with locally advanced HNSCC who were treated with induction chemotherapy followed by concurrent chemoradiotherapy (CRT; induction chemotherapy/CRT; N = 144) and CRT alone (N = 80) from 2005 to 2013. We analyzed OS and progression-free survival (PFS).
RESULTS: The 3-year OS rate was significantly higher in the induction chemotherapy/CRT group compared to the CRT group (74.0% vs 62.7%; p = .045). The 3-year PFS rate was 64.6% in the induction chemotherapy/CRT group and 54.1% in the CRT group (p = .060). Subgroup analysis showed patients with high N classification (N2 or N3) oropharyngeal cancer had greater benefits when treated with induction chemotherapy/CRT.
CONCLUSION: Induction chemotherapy plus CRT improved OS, compared to CRT alone in locally advanced HNSCC, especially with high N classification.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  concurrent chemoradiotherapy; head and neck cancer; induction chemotherapy; subgroup analysis; survival

Mesh:

Year:  2015        PMID: 26104823     DOI: 10.1002/hed.23891

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  8 in total

1.  Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma.

Authors:  Chan-Young Ock; Bongjun Son; Bhumsuk Keam; Seung-Youn Lee; Jaewoo Moon; Hwanjong Kwak; Sehui Kim; Tae Min Kim; Yoon Kyung Jeon; Seong Keun Kwon; J Hun Hah; Se-Hoon Lee; Tack-Kyun Kwon; Dong-Wan Kim; Hong-Gyun Wu; Myung-Whun Sung; Dae Seog Heo
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-16       Impact factor: 4.553

2.  PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma.

Authors:  Chan-Young Ock; Sehui Kim; Bhumsuk Keam; Miso Kim; Tae Min Kim; Jin-Ho Kim; Yoon Kyung Jeon; Ju-Seog Lee; Seong Keun Kwon; J Hun Hah; Tack-Kyun Kwon; Dong-Wan Kim; Hong-Gyun Wu; Myung-Whun Sung; Dae Seog Heo
Journal:  Oncotarget       Date:  2016-03-29

3.  Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma.

Authors:  Chan-Young Ock; Sehui Kim; Bhumsuk Keam; Soyeon Kim; Yong-Oon Ahn; Eun-Jae Chung; Jin-Ho Kim; Tae Min Kim; Seong Keun Kwon; Yoon Kyung Jeon; Kyeong Chun Jung; Dong-Wan Kim; Hong-Gyun Wu; Myung-Whun Sung; Dae Seog Heo
Journal:  Oncotarget       Date:  2017-06-16

4.  A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.

Authors:  Bhumsuk Keam; Keun-Wook Lee; Se-Hoon Lee; Jin-Soo Kim; Jin Ho Kim; Hong-Gyun Wu; Keun-Yong Eom; Suzy Kim; Soon-Hyun Ahn; Eun-Jae Chung; Seong Keun Kwon; Woo-Jin Jeong; Young Ho Jung; Ji-Won Kim; Dae Seog Heo
Journal:  Oncologist       Date:  2019-02-22

5.  Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment?

Authors:  Shin Hye Yoo; Chan-Young Ock; Bhumsuk Keam; Sung Joon Park; Tae Min Kim; Jin Ho Kim; Yoon Kyung Jeon; Eun-Jae Chung; Seong Keun Kwon; J Hun Hah; Tack-Kyun Kwon; Kyeong Chun Jung; Dong-Wan Kim; Hong-Gyun Wu; Myung-Whun Sung; Dae Seog Heo
Journal:  Korean J Intern Med       Date:  2018-11-16       Impact factor: 2.884

6.  Matched pair analysis for comparison of survival outcome of alternative regimens to standard three-weekly cisplatin-based concurrent chemoradiation of head and neck cancer.

Authors:  Hye Ri Han; Sung Jun Ma; Gregory M Hermann; Austin J Iovoli; Kimberly E Wooten; Hassan Arshad; Vishal Gupta; Ryan P McSpadden; Moni A Kuriakose; Michael R Markiewicz; Jon M Chan; Mary E Platek; Andrew D Ray; Fangyi Gu; Wesley L Hicks; Anurag K Singh
Journal:  Ann Transl Med       Date:  2021-05

7.  Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study.

Authors:  Ryul Kim; Chan-Young Ock; Bhumsuk Keam; Tae Min Kim; Jin Ho Kim; Jin Chul Paeng; Seong Keun Kwon; J Hun Hah; Tack-Kyun Kwon; Dong-Wan Kim; Hong-Gyun Wu; Myung-Whun Sung; Dae Seog Heo
Journal:  BMC Cancer       Date:  2016-02-17       Impact factor: 4.430

8.  Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).

Authors:  Yun-Gyoo Lee; Eun Joo Kang; Bhumsuk Keam; Jin-Hyuk Choi; Jin-Soo Kim; Keon Uk Park; Kyoung Eun Lee; Jung Hye Kwon; Keun-Wook Lee; Min Kyoung Kim; Hee Kyung Ahn; Seong Hoon Shin; Hye Ryun Kim; Sung-Bae Kim; Hwan Jung Yun
Journal:  BMC Cancer       Date:  2020-08-27       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.